A5070243247- PI3K/AKT/mTOR signaling in cancer
- Cancer-related Molecular Pathways
- Liver Disease Diagnosis and Treatment
- Cancer Mechanisms and Therapy
- Inflammatory mediators and NSAID effects
- Wnt/β-catenin signaling in development and cancer
- RNA Interference and Gene Delivery
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer, Lipids, and Metabolism
- Melanoma and MAPK Pathways
- Marine Biology and Environmental Chemistry
- Cell death mechanisms and regulation
- Cytokine Signaling Pathways and Interactions
- Nanoparticle-Based Drug Delivery
- Cell Adhesion Molecules Research
- Endoplasmic Reticulum Stress and Disease
- Estrogen and related hormone effects
- Synthesis and biological activity
- Ubiquitin and proteasome pathways
- Curcumin's Biomedical Applications
- Cancer-related gene regulation
- Invertebrate Immune Response Mechanisms
- Cancer Cells and Metastasis
- Epigenetics and DNA Methylation
- Berberine and alkaloids research
National Research Council
2016-2025
Institute for Biomedical Research and Innovation
2010-2025
National Academies of Sciences, Engineering, and Medicine
2006-2023
Istituto di Biomedicina e di Immunologia Molecolare Alberto Monroy
2010-2019
University of Palermo
2002-2014
East Carolina University
2012
Consorzio Roma Ricerche
2012
University of Verona
2012
Clinica Luganese Moncucco
2011
Ministry of Education, Universities and Research
2006
A bstract : The incidence of hepatocellular carcinoma is increasing in many countries. estimated number new cases annually over 500,000, and the yearly comprises between 2.5 7% patients with liver cirrhosis. varies different geographic areas, being higher developing areas; males are predominantly affected, a 2:3 male/female ratio. heterogeneous distribution reflects epidemiologic impact main etiologic factors environmental risk, which hepatitis B (HBV) C (HCV) viruses. percentage...
Sorafenib, a multikinase inhibitor, recently received FDA approval for the treatment of advanced hepatocellular carcinoma (HCC). However, as clinical application sorafenib evolves, there is increasing interest in defining mechanisms underlying its anti-tumor activity. Considering that this specific inhibitor could target unexpected molecules depending on biologic context, precise understanding mechanism action be critical to maximize efficacy, while minimizing adverse effects. Two human HCC...
Abstract Sorafenib, an oral multikinase inhibitor, is the only approved agent for treatment of advanced hepatocellular carcinoma (HCC). However, its benefits are modest, and as mechanisms action remain elusive, a better understanding anticancer effects needed. Based on our previous study results, we investigated here implication nuclear protein 1 (NUPR1) in HCC role sorafenib treatment. NUPR1 stress-inducible that overexpressed various malignancies, but not yet fully understood. We found...
Liver cirrhosis (LC), the end stage of many forms chronic hepatitis different etiologies is a diffuse process characterized by fibrosis and conversion normal liver architecture into structurally abnormal nodules surrounded annular fibrosis.This progressive clinical condition, leads to cell failure portal hypertension, which can favour onset hepatocellular carcinoma.Defining phase natural history crucial for therapeutic choice prognosis.Liver biopsy currently considered best available...